Tosymra® is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: Use only if a clear diagnosis of migraine has been established. Tosymra® is not indicated for the prevention of migraine or treatment of cluster headache.

Tosymra® is contraindicated in patients with a history of hemiplegic or basilar migraine. This is not the only contraindication for Tosymra®.

Fast, ready-to-use migraine pain relief1-3

10 minutes

Tosymra® delivers migraine pain relief in as little as 10 minutes with just one spray for some patients (13% vs. 5% for placebo).*1-3

Efficacy of Tosymra® is based on relative bioavailability to subcutaneous sumatriptan at a dose of 4 mg. In a clinical study, this dose of sumatriptan resulted in 57% of patients achieving pain relief at 2 hours vs. 21% for placebo.1

*Time to onset and degree of pain relief varies by patient.

About Tosymra
intravail

Tosymra® uses the science of Intravail®

Tosymra® is the first and only triptan nasal spray to use the novel ingredient Intravail® to enhance drug absorption across the nasal mucosa.4

How It Works

Tosymra® for as little as $0†

The Access Pathways® Program is a best-in-class savings and support program. Access Pathways®, in partnership with Blink Pharmacy Plus, offers:

Eligible commercially insured patients may pay as little as $0† per prescription, per month with free home delivery through Blink Pharmacy Plus

Fast, free
home delivery

Dedicated customer support to guide you and your patients through the process

Savings Program

†Restrictions and quantity limits apply.  Click to view complete program terms and conditions. Medicare, Medicaid, and other federal and state healthcare program patients are not eligible.

Tosymra® is simple to administer

See the Instructions for Use.

Single-use, 10 mg dosage

Fine mist-like spray

Discreet size can be
taken anywhere

Learn more

Want more information?

Sign up today to learn more about Tosymra®.

*All fields required.


Privacy Policy and Authorization

By clicking the submit button below, you consent to the use by Upsher-Smith Laboratories, LLC and its third parties of the information you have provided to periodically send you information about Tosymra® or other products and promotions.

Upsher-Smith Laboratories, LLC and its third parties use the information you provide for legitimate business purposes only and will not sell, share, or otherwise distribute your personal information to third parties. By joining, you acknowledge that your consent to receive automated messages is not required as a condition to purchase goods and services.


References

  1. Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
  2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
  3. Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.
  4. Maggio ET. Intravail®: highly effective intranasal delivery of peptide and protein drugs. Expert Opinion Drug Delivery. 2006;3(4):529-539.